The following are appropriate products for inclusion in this focused issue:
*Autologous anti-cancer vaccines: such as autologous vaccines derived from whole tumor or autologous tumor derived heat shock proteins, autologous dendritic cell vaccines including autologous dendritic cells loaded with other antigens/adjuvants (such as sipuleucel-T) and autologous dendritic cells loaded with autologous tumor antigens (whether from autologous whole tumor, allogeneic tumor, autologous tumor cell line, or selected neoantigens) or autologous dendritic cell vaccines loaded with a combination of antigens based on tumor phenotype.
*Autologous tumor infiltrating lymphocytes
*Autologous lymphokine activated killer (LAK) cells or cytokine-induced killer (CIK) cells, or autologous natural killer cells
*CART or TCR autologous cytotoxic T lymphocytes
*Intratumor injections of immune stimulating agents such as talimogene lahareparvec (TVEC)
